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Abstract
Background: Since its appearance in 2009, the pandemic influenza A(H1N1) virus circulated worldwide causing several
severe infections.
Methods: Respiratory samples from patients with 2009 influenza A(H1N1) and acute respiratory distress attending 24
intensive care units (ICUs) as well as from patients with lower respiratory tract infections not requiring ICU admission and
community upper respiratory tract infections in the Lombardy region (10 million inhabitants) of Italy during the 2010–2011
winter-spring season, were analyzed.
Results: In patients with severe ILI, the viral load was higher in bronchoalveolar lavage (BAL) with respect to nasal swab (NS),
(p,0.001) suggesting a higher virus replication in the lower respiratory tract. Four distinct virus clusters (referred to as
cluster A to D) circulated simultaneously. Most (72.7%, n=48) of the 66 patients infected with viruses belonging to cluster A
had a severe (n=26) or moderate ILI (n=22). Amino acid mutations (V26I, I116M, A186T, D187Y, D222G/N, M257I, S263F,
I286L/M, and N473D) were observed only in patients with severe ILI. D222G/N variants were detected exclusively in BAL
samples.
Conclusions: Multiple virus clusters co-circulated during the 2010–2011 winter-spring season. Severe or moderate ILI were
associated with specific 2009 influenza A(H1N1) variants, which replicated preferentially in the lower respiratory tract.
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Introduction
The emergence of a new pandemic influenza A strain in 2009
has raised global concerns for health organizations. Although
moderate in general, severe cases of influenza-like illness (ILI)
during the 2009 pandemic have been associated with the
emergence of specific virus variants. In particular, the D222G or
N mutations have been observed in cases of severe disease [1–3].
Since its emergence, the 2009 influenza A(H1N1) virus has
evolved and seven distinct clades have been reported so far [4,5].
Early findings from the 2010–2011 season have shown the
circulation of two virus variants in the UK as well as in New
Zealand, Australia and Singapore [6,7]. The reasons for this wide
variation could be ascribed both to the global spread of 2009
influenza A(H1N1) virus and to its circulation in the human
population for more than one year. The molecular characteriza-
tion of circulating viral variants is crucial for a timely identification
of any change that may increase virulence.
The aim of this study was to investigate the prevalence of 2009
influenza A(H1N1) variants with mutated hemagglutinin (HA) in
upper and lower respiratory tract of patients with severe infections.
In the framework of the severe influenza A surveillance program in
Lombardy (Northern Italy, nearly10 million inhabitants out of a total
of about 60 million), our reference laboratories collected respiratory
s a m p l e sf r o mp a t i e n t sa d m i t t e dt oi n t e n s i v ec a r eu n i t s( I C U s )a sw e l l
as from inpatients hospitalized at units other than ICUs, and from
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practitioners. Patients were stratified according to strict clinical
criteria, and 2009 A(H1N1) HA sequences were analyzed in severe
cases and in a comparable number of moderate and mild cases.
Particular consideration was paid both to the three structural
elements (190-helix, 220-loop and 130-loop) in the HA involved in
receptor binding site (RBS) domains and to the four antigenic sites
(Sa, Sb, Ca and Cb), where point mutations could alter the ability
of the virus to infect cells and the antibody reactivity [8].
Materials and Methods
Study population and clinical outcome
From November 1, 2010 to March 6, 2011, nasal swab (NS) and/
or bronchoalveolar lavage (BAL) specimens collected from 45
patients with severe ILI admitted to 24 ICUs in the Lombardy
region were analyzed. A comparable number of patients with
moderateILI (N=40)ormildILI(N=54) were analyzed in parallel.
Analyses were carried out at S.S. Virologia Molecolare, Fondazione
IRCCS Policlinico San Matteo, Pavia or Dipartimento di Sanita `
Pubblica-Microbiologia-Virologia, Universita ` degli Studi di Milano.
Patients were stratified using the criteria proposed by Zar-
ychanski et al. [9] as follows: i) severe ILI, consisting of critically ill
patients with acute respiratory distress syndrome (ARDS)
characterized by bilateral alveolar infiltrates on chest radiography
and rapidly progressive hypoxemia [10], admitted to ICUs for
mechanical ventilation or extra-corporeal membrane oxygenation
(ECMO); ii) moderate ILI, (positive chest radiography and/or
reduced O2 blood saturation, pO2,90%) consisting of lower
respiratory tract infection requiring admission to units other than
ICUs for antiviral and/or oxygen supplementation by non-
invasive assisted ventilation procedures; and iii) mild ILI,
consisting of upper respiratory tract infection reported by sentinel
practitioners and not requiring admission to hospital and
administration of antiviral drugs or oxygen supplementation.
Ethics statement
The local Ethics Committee consent was not required since
according to a Regional Surveillance and Preparedness Plan (DGR
IX/1046, 22 Dec. 2010 and DGR 5988, 30 Jun 2011), diagnostic
and clinical management of patients admitted at hospitals in the
Lombardy Region with severe and moderate ILI included
prospective influenza A detection, subtyping and sequencing which
was centralized at the two Regional Reference Laboratories
(Molecular Virology Unit, IRCCS Policlinico San Matteo, Pavia
and Dipartimento di Sanita ` Pubblica-Microbiologia-Virologia,
Universita ` degli Studi di Milano, Milan). Mild respiratory infections
were collected by sentinel pratictioners and anonymously analyzed
at the reference laboratory in Milan, in the frame of the National
Surveillance Plan (Influnet). Informed consent was not necessary
since patients with severe and mild ILI were included in a Regional
diagnostic and clinical management protocol. Data were anony-
mously analyzed according to a Regional Surveillance and
Preparedness Plan. Mild ILI were collected and analyzed within
the National Surveillance Plan (Influnet).
Virus detection and quantification
Detection and quantification of influenza A viruses was routinely
performed on NS specimens by a real-time RT-PCR developed at
the Centers for Disease Control, Atlanta, USA and available on the
WHO website: (http://www.who.int/csr/resources/publications/
swineflu/CDCrealtimeRTPCRprotocol_20090428.pdf). In a sub-
set of patients influenza A quantification could be performed on
both NS and BAL specimens.
Sequencing of the hemagglutinin gene
The 2009 influenza A(H1N1) HA gene was amplified directly
from clinical specimens using the Superscript III One-step RT-
PCR amplification kit (Invitrogen, Carlsbad, USA). Primer
sequences were as follows: forward primer, HA-F0 (nt 1–28) 59-
ATGAAGGCAATACTAGTAGTTCTGCT-39, reverse primer,
HA-R0 (nt 1681–1657) 59-GTAGAGACCCATTAGAGCA-
CATCCA-39. The PCR product was purified using a Microcon-
100 microconcentrator following manufacturer’s instructions
(Millipore, Bedford, MA, USA). Purified PCR products were
sequenced using the BigDye Terminator Cycle-Sequencing kit
(Applied Biosystem, Foster City, USA) with an ABI Prism 3100
DNA sequencer (Applied Biosystems, Foster City, USA).
Phylogenetic analysis
Sequences were assembled using the Sequencher software,
version 4.6 (Gene Codes Corporation, Ann Arbor, USA).
Nucleotide alignments were constructed using the ClustalW
method with MEGA version 4.1 software [11]. Phylogenetic trees
were generated using neighbour-joining distance method with a
Kimura 2-parameter as an evolutionary model. The bootstrap
analysis performed to evaluate the reliability of the inferred tree
included 1,000 replicates. Amino acids were numbered starting
after the signal peptide (DTLC). Potential N-linked glycosylation
sites were predicted using the NetNGlyc 1.0 Server [12].
NCBI GenBank accession numbers for our nucleotide sequenc-
es are JF801855-JF801909 and JN017095-JN017181.
Statistical analysis
Comparison of viral loads from paired respiratory samples was
performed with the Wilcoxon rank sum test for continuous paired
variables. The Fisher’s exact test for categorical variables was used
for analysis of mutation frequencies between groups of patients.
Results
Demographic, virologic and clinical characteristics of
study patients
This study included 139 patients with a 2009 influenza
A(H1N1) virus infection: 45 (32.4%) critically ill patients with
severe ILI, 40 (28.8%) patients with moderate ILI and 54 (38.8%)
patients with mild ILI.
As shown in Table 1, the median age of patients with severe ILI
was significantly higher than that of patients with mild ILI, while
no difference was observed in comparison with moderate ILI
patients. The overall percentage of male patients (61.9%) was 1.6
fold greater than that of females (38.1%), and the male/female
ratio was 1.8 in both severe and moderate ILI groups and 1.3 in
the mild ILI group (Table 1). NS samples were available for all
patients, as these specimens were routinely sent to the laboratories
for diagnosis of 2009 influenza A(H1N1).
In the 13 patients with paired NS and BAL samples (12 severe
ILI and 1 moderate ILI), virus load was significantly higher in the
lower respiratory tract secretions (median 2.2610
7 RNA copies/
ml, range 7610
4–3.8610
8 RNA copies/ml) than in upper
respiratory tract samples (median 4.2610
4 RNA copies/ml, range
1–1.4610
7; p=0.003) (Figure 1A).
Phylogenetic analysis
The overall nucleotide identity of analyzed HA sequences with
the reference vaccine strain A/California/07/2009(H1N1) ranged
between 98.2% and 99.6%, with a maximum of 13 amino acid
changes.
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distributed in the region and among the 24 ICUs. Phylogenetic
analysis showed the simultaneous circulation of four distinct virus
clusters referred to as clusters A, B, C and D (Figure 2B). Cluster A
was characterized by the amino acid mutations R205K, I216V
and V249L and included 66/139 (47.5%) sequences. Sequences
belonging to cluster A were detected more frequently in patients
with severe (n=26) or moderate ILI (n=22) than in those with
mild ILI (n=18) (72.7% vs 27.3%; p,0.001) (Figure 2B). Two
sequences identified in deceased patients (A/Pavia/127/2011 and
A/Milano/166/2011) fell into cluster A. Two sub-clusters (A1 and
A2) were also described. Cluster A1 was characterized by H138Q
and E356A substitutions, never reported previously. Cluster A2,
characterized by mutation E356G, was closely related to a strain
observed in Sweden (i.e. A/Stockholm/9/2010, A.N. EPI301389).
Twenty-four (17.3%) virus sequences belonged to cluster B and
were characterized by the N125D substitution (Figure 2B). In this
cluster, two virus strains with an additional mutation (D94E) were
observed in two deceased patients from different ICUs (A/Pavia/
37/2011 and A/Milano/26/2011).
Cluster C, containing 37 (26.6%) sequences, was characterized
by S185T and S451N substitutions, and corresponded to a cluster
observed in the UK [6]. Three out of seven (42.9%) virus
sequences from deceased patients belonged to this cluster. Two
additional amino acid substitutions (S143G and A197T) were
observed in three virus sequences from patients with mild ILI (A/
Pavia/44/2011, A/Pavia/78/2011, and A/Milano/94/2011).
Cluster D, which included 12 (8.6%) sequences, was closely
related to one of the two clusters circulating in the UK during the
2010–2011 seasonal epidemic [3]. This cluster was characterized
by A134T and S183P mutations. Three additional mutations
(A141S, I295V and V479I) were observed in 10/12 (83.3%)
sequences. In contrast with the other three clusters, the
substitution E374K was absent in this cluster. Nine out of 12
(75.0%) sequences in this cluster were from patients with mild ILI,
while no sequences from patients with severe infections were
detected in this cluster.
Analysis of receptor binding site domains, antigenic
epitopes and glycosylation sites
Most amino acid substitutions were located in the HA1 region
containing the major antigenic epitopes. All sequences analyzed
belonged to clade 7 and were characterized by the fixed amino
acid mutation S203T (Figure 3).
Several HA mutations were observed throughout the three
patient groups. On the whole, 59 HA residue positions were found
with at least one change compared to vaccine reference strain A/
California/07/2009(H1N1) (Figure 3). Overall, a greater number
of changes was observed in patients with mild (41/59, 69.5%) than
Table 1. Demographic and clinical data in groups of patients analyzed.
Group of patients (no.) P value
b
Data
All patients
(N=139) Severe (45) Moderate (40) Mild (54)
Severe vs
Mild
Severe vs
Moderate
Moderate vs
Mild
Gender Number (%)
Male 86 (61.9%) 29 (64.4%) 26 (65.0%) 31 (57.4%)
Female 53 (38.1%) 16 (35.6%) 14 (35.0%) 23 (42.6%)
Age
a
Median (years) 47 52 49 34 0.01 ns ns
Range 1 mo-85 25–83 1 mo-85 1–83
mo, month.
afor one patient this information was not available.
bP value.0.10 is considered not significant (ns); significant P value under 0.05 is in bold.
doi:10.1371/journal.pone.0028332.t001
Figure 1. Paired samples analysis. A: Comparison of viral load in
paired nasal swabs (NS) and bronchoalveolar lavage (BAL) samples. B:
Distribution of 222 polymorphisms in paired NS and BAL specimens.
NA, not available; ND, not done due to low viral load.
doi:10.1371/journal.pone.0028332.g001
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ILI (32/59, 54.2%, p=0.12).
The frequency of mutations in RBSs, antigenic sites and amino
acids fixed in each cluster among patient groups was investigated
(Table 2). The R205K, I216V, D222G, and V249L changes were
found more frequently in patients with severe ILI than in those
with mild ILI (p=0.009). Conversely, the N125D, A134T,
A141S/T, S183P, and I295V changes were detected more
frequently in patients with mild ILI than in patients with severe
ILI (p,0.05). The substitutions H138Q, R205K, I216V, D222G/
N/Y, and V249L were identified more frequently in patients with
severe and moderate ILI than in those with mild ILI (Table 2).
Mutations V26I, I116M, A186T, D187Y, D222G/N, M257I,
S263F, I286L/M, and N473D were observed only in patients with
severe ILI (Figure 3). All these mutations except those at position
222 were present only in single or dual sequences.
D222G/N amino acid changes were detected more frequently
in sequences from patients with severe ILI (8/45; 17.7%) than in
those from patients with mild (0/54, 0%; p=0.01) or moderate
ILI (0/40, 0%; p=0.03). The D222G/N changes were observed
only in BAL samples from five patients with severe ILI, while the
HA sequences in the paired NS samples showed the wild-type
222D (Figure 1B). In addition, an amino acid change from aspartic
acid (D) to tyrosine (Y) at residue 222 was observed in the HA
sequences of viruses detected in two patients hospitalized in the
same hematology ward at IRCCS Policlinico San Matteo: one
presented with pneumonia and the other one with mild respiratory
symptoms. Interestingly, the HA sequences carrying mutations at
residue 222 did not segregate in a particular virus cluster, but were
evenly distributed in clusters A, B and C (Figure 2B).
Besides D222G/N changes, an additional mutation in the RBS
domain (D187Y) was observed. It was detected only in viruses
from two patients with severe ILI, one requiring mechanical
ventilation and the other requiring an ECMO procedure.
To address the difference in antigenic properties, the mutations
in antigenic epitope regions (Sa, Sb, Ca1, Ca2 and Cb) were
investigated (Figure 3). In all sequences, the change S203T in the
antigenic site Ca1 was present as a fixed mutation characterizing
sequences belonging to clade 7. A maximum of 10 mutations
(excluding the S203T) were found in the antigenic sites. In
particular, two in antigenic site Sa (N125D, and S162N ), two in
antigenic site Sb (S185T and D187Y), one in antigenic site Ca1
(R205K), three in antigenic site Ca2 (H138Q, A141S/T, and
D222G/N/Y), and two in antigenic site Cb (L70H and S74N).
Three of these substitutions were found exclusively in patients with
mild ILI (L70H, S74N, and S162N).
Six potential N-glycosylation sites were found in all HA
sequences analyzed and corresponded with positions 11, 23, 87,
277, 287, and 482. The sequence named A/Pavia/09/2011
possessed an additional N-glycosylation site at residue 163 due to
an amino acid change from serine (S) to asparagine (N), with a
glycosylation score of 0.727. This patient presented with mild
symptoms of ILI.
Discussion
This study was aimed at investigate the prevalence of 2009
influenza A(H1N1) variants with mutated hemagglutinin (HA) in
upper and lower respiratory tract of patients with severe infections
in the 2010–2011 seasonal epidemic to extend observations
reported during the 2009 pandemic [1–3].
In keeping with preliminary data published in the ECDC report
released in February [13], the simultaneous circulation of four
2009 influenza A(H1N1) clusters in a geographical area including
approximately 1/6 of the total Italian population (about 10/60
million inhabitants) was observed. Cluster A, characterized by
mutations R205K, I216V and V249L, included about half of the
analyzed HA sequences. Interestingly, nearly 70% of the patients
infected with viruses belonging to this cluster developed either a
severe or a moderate ILI. In contrast, clusters B, C, and D were
observed with similar frequency in all patients categories. Cluster
C represented about one-fourth of analyzed sequences. This result
is partially in agreement with the ECDC report that described
viruses harboring the S185T mutation as the variants showing the
greatest expansion and geographic spread in Europe [13]. Of note,
about half of deceased patients in both our series and the UK
series were infected by viruses belonging to this cluster [6,13].
Cluster D, characterized by A134T and S183P substitutions, was
closely related to a cluster recently reported to circulate in the
United Kingdom, Australia, New Zealand and Singapore [6,7,13].
The substitution E374K, previously reported to alter the stability
of HA trimer [14] which was fixed in the others three clusters, was
absent in sequences belonging to cluster D.
In the molecular analysis of HA sequences, particular attention
was paid to the amino acid variations occurring in the HA
structural elements involved in both the receptor-binding sites and
the antigenic sites. Some of the substitutions observed were
prominently exposed on the surface of the HA trimer (at residue
125, 134, 183, 185, 216) but others were buried. With respect to
the reference vaccine strain A/California/07/2009(H1N1), a
higher number of amino acid changes in the antigenic sites and,
to a lower extent, in RBSs was observed in virus strains from
patients with mild ILI than in those with severe or moderate ILI.
This suggests that HA divergence in virus strains sustaining mild
upper respiratory tract infections thus expressing a great spreading
capacity might be the result of multiple rounds of selection by herd
immunity. In contrast, the HA sequences of virus strains from
patients with a severe infection were genetically more conserved,
probably due to the evolutionary bottleneck represented by the
receptor specificity. In fact, virus variants associated with severe
infection are sequestered in the lower respiratory tract and, hence,
the switch of receptor specificity of these viruses from a2-6 to a2-3-
linked sialosides seems to decrease the capacity of the virus to
infect the upper respiratory tract, thus impairing the spreading
ability of those aggressive variants.
Consistent with data reported during the 2009 pandemic
[1,2,15], the D222G/N variants were more frequently detected in
patients with a severe influenza infection than in those with mild
ILI. In addition, the analysis of paired NS and BAL samples
showed that the 222G/N substitutions were found exclusively in
the lower respiratory tract specimens supporting the hypothesized
switch of receptor specificity from a2-6 to a2-3-linked sialosides
[3].
In our series, D222Y variants, previously reported in severe
cases [5], were detected in two epidemiologically but not clinically
linked patients, since they attended the same hospital ward but had
Figure 2. Geographic and phylogenetic strains distribution. A: Geographic distribution of patients categorized by clinical outcome. B:
Phylogenetic tree based on influenza 2009 A(H1N1) viruses HA nucleotide sequences. Sequences of strains circulating in 2009–2011 are represented
in italics (NCBI accession numbers or GISAID numbers are provided). NCBI GenBank accession numbers for our nucleotide sequences are JF801855-
JF801909 and JN017095-JN017181. {, deceased patient.
doi:10.1371/journal.pone.0028332.g002
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ARDS and, thus, our data could not corroborate the increased
virulence of these variants. Although the D187Y substitution was
detected exclusively in two patients with severe ILI, no conclusive
considerations on the increased virulence of these variants can be
drawn. This amino acid substitution has been previously detected
in a virus circulating in Brazil (A/Brasil/7450/2009) and, more
recently, in an isolate from England (A/England/4500186/2010).
However, no clinical data from patients carrying this viral variant
were available.
Further studies on the receptor binding specificity and affinity
will clarify both the role of such HA mutants on viral tropism and
their contribution to exacerbation of disease.
In this study, patients with severe influenza infections showed a
significantly higher viral load in lower respiratory tract secretions
compared to paired upper respiratory tract ones. These findings
confirm and extend the data found in the 2009 influenza
pandemic [2], and further stress the importance of systematically
analyzing BAL samples in patients with severe influenza A
infection. It is worth mentioning that influenza surveillance data
are based upon the analysis of upper respiratory tract samples only
[6,7] and thus, could fail to spot the emergence of more aggressive
variants in the lower respiratory tract [16].
A limitation of this study is the relatively small set of data
analyzed and the pathogenetic role of the virus mutants observed
remains to be confirmed in a larger cohort. On the other hand, the
infection by the 2009 influenza A(H1N1) strain was moderate in
general and the prospective enrollment, according to strict clinical
criteria, of 45 critically ill patients required the combined effort of
24 ICUs. Thus, this data set, although limited, appears unique to
Table 2. Prevalence of notable mutations in receptor binding sites, antigenic sites (Sa, Sb, Ca1, Ca2 and Cb) and amino acids fixed
in each cluster among patient categories.
Patient categories (no.) P value
b,c
Location of mutations Mutations
a Severe (45) Moderate (40) Mild (54)
Severe vs
Mild
Severe/Moderate
vs Mild
Severe vs
Moderate
Moderate vs
Mild
Receptor Binding
Sites
Loop 220 D222G/N/Y 8/45 (17.8%) 1/40 (2.5%) 1/54 (1.8%) 0.01 0.08 0.03 nns
D222N 3/45 (6.7%) 0/40 (0%) 0/54 (0%) 0.09 ns ns ns
D222G 5/45 (11.1%) 0/40 (0%) 0/54 (0%) 0.02 ns 0.06 ns
D222Y 0/45 (0%) 1/40 (2.5%) 1/54 (1.8%) ns ns ns ns
I216V 26/45 (57.8%) 22/40 (55.0%) 18/54 (33.3%) 0.02 0.009 ns 0.06
I216T 1/45 (2.2) 1/40 (2.5%) 0/54 (0%) ns ns ns ns
Helix 190 S183P 0/45 (0%) 3/40 (7.5%) 9/54 (16.7%) 0.004 0.01 0.10 ns
A186T 1/45 (2.2%) 0/40 (0%) 0/54 (0%) ns ns ns ns
D187Y 2/45 (4.4%) 0/40 (0%) 0/54 (0%) ns ns ns ns
Loop 130 A134T 0/45 (0%) 3/40 (7.5%) 9/54 (16.7%) 0.004 0.01 0.10 ns
Antigenic sites Sa N125D 7/45 (15.5%) 1/40 (2.5%) 16/54 (29.6%) 0.05 0.001 0.06 ,0.001
S162N 0/45 (0%) 0/40 (0%) 1/54 (1.8%) ns ns ns ns
K163R 0/45 (0%) 1/40 (2.5%) 0/54 (0%) ns ns ns ns
Sb S185T 12/45 (26.7%) 13/40 (32.5) 12/54 (22.2%) ns ns ns ns
D187Y 2/45 (4.4%) 0/40 (0%) 0/54 (0%) ns ns ns ns
Ca1 R205K 27/45 (60.0%) 22/40 (55.0%) 18/54 (33.3%) 0.009 0.005 ns 0.06
Ca2 H138Q 21/45 (46.7%) 21/40 (52.5%) 17/54 (31.5%) ns 0.05 ns 0.08
A141S/T 0/45 (0%) 5/40 (12.5%) 10/54 (18.5%) 0.001 0.02 0.02 ns
Cb L70H 0/45 (0%) 0/40 (0%) 1/54 (1.8%) ns ns ns ns
S74N 0/45 (0%) 0/40 (0%) 1/54 (1.8%) ns ns ns ns
Cluster A V249L 26/45 (57.8) 22/40 (55.0%) 18/54 (33.3%) 0.03 0.009 ns 0.06
E356A/G
c 20/38 (52.6%) 17/31 (54.8%) 17/45 (37.8%) ns ns ns ns
Cluster B D94E 4/45 (8.9%) 0/40 (0%) 4/54 (7.4%) ns ns ns ns
Cluster C S451N
c 11/38 (28.9%) 9/32 (28.1%) 9/45 (20.0%) ns ns ns ns
Cluster D I295V
c 0/43 (0%) 2/38 (5.3%) 8/52 (15.4%) 0.007 0.01 ns ns
aAmino acids numbering start after signal peptide DTLC.
bP value.0.10 is considered not significant (ns); P value between 0.05 and 0.10 was considered a trend of significance; significant P value under 0.05 are in bold.
cData not available for all sequences.
doi:10.1371/journal.pone.0028332.t002
Figure 3. Amino acids changes with respect to vaccine strains (A/California/07/2009). The amino acid changes in the receptor binding
sites (RBS) are highlighted in black. The amino acid changes in the antigenic sites are highlighted in grey. {, deceased patient; URTI, upper respiratory
tract infection; LRTI, lower respiratory tract infection; ARDS, acute respiratory disease syndrome.
doi:10.1371/journal.pone.0028332.g003
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A(H1N1). Although the comparison of different respiratory
specimens might be questionable, our data are in agreement with
results by Giannella et al [17] describing a reduced viral load in
the upper vs lower respiratory tract of patients with severe
influenza infections. Finally, others factors such as the host
immune response and the existence of co-morbidities should be
taken into account when evaluating severe infection outcome.
In conclusion, our results highlight that HA D222G/N
mutation was detected exclusively in lower respiratory tract
secretions. The findings of this study on the circulation of new
variants of 2009 influenza A(H1N1) stress the importance of
continuous monitoring of influenza virus evolution. Prompt
analysis of severe infections by adopting appropriate sampling
guidelines will promote better understanding of the epidemiology
of mutated viruses with respect to clinical outcome.
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